Richard J. Willke, PhD, chief science officer of ISPOR, previews the discussions at the ISPOR 22nd Annual International Meeting, which will be held May 20-24 in Boston, Massachusetts, including topics on the future of health policy in the United States and social networking interventions.
Richard J. Willke, PhD, chief science officer of ISPOR, previews the discussions at the ISPOR 22nd Annual International Meeting, which will be held May 20-24 in Boston, Massachusetts, including topics on the future of health policy in the United States and social networking interventions.
Transcript
As ISPOR prepares for the annual meeting in Boston in May, how is it handling the uncertainty of an Affordable Care Act repeal? What other topics will the meeting focus on?
Our first plenary in Boston is going to feature a panel of 4 leading health economists. Two that have worked with the Democrats—Jonathan Gruber and David Cutler—and 2 that have tended to work with Republicans—Joe Antos and Gail Wilensky. Given what just happened [with the American Health Care Act] we expect it to be a very lively discussion.
Our second plenary is on the leading edge of how we look at healthcare behaviors. It's called "Social Networking Interventions and Population Health." And it's being given by Nicholas Christakis of Yale. I'm really anxious to hear that one. And our third one will be very aligned with what we talked about [at AMCP 2017]. The title is "When Do You Really Need Randomized Clinical Trials?" And we'll have Sebastian Schneeweiss and Rob Califf, who was just FDA commissioner, and Steven Goodman to talk about those topics.
Plus, about another 100 sessions on a variety of current scientific and policy topics. So we're really excited about it.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More